Position in AZN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$28,727,430
New position
Shares Held
151,500
first reported quarter
Ownership
0.010%
of shares outstanding
% of Portfolio
2.71%
of 13F equity value
Holder Rank
#195
of 1,459 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Rhenman & Partners Asset Management AB holds $173,015,372 across 8 Drug Manufacturers - General names. AZN ranks #1 (16.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
This page
|
151,500 | $28,727,430 | |
| 2 | MRK |
Merck & Co., Inc.
|
213,500 | $27,434,750 | |
| 3 | LLY |
ELI LILLY & Co
|
22,315 | $26,765,282 | |
| 4 | ABBV |
AbbVie Inc.
|
96,775 | $24,352,461 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
178,250 | $22,520,105 | |
| 6 | BIIB |
Biogen Inc.
|
94,850 | $20,493,291 | |
| 7 | JNJ |
Johnson & Johnson
|
72,500 | $18,412,825 | |
| 8 | AMGN |
Amgen Inc
|
11,900 | $4,309,228 |
All Filings in AZN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $28,727,430 | 151,500 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||